EPS: As of FY2025 Q2, the actual value is USD 0.22.

Segment Revenue

• The company has not generated any operating revenues as of June 30, 2025, as it is still in the process of identifying a target for its initial business combination.

Operational Metrics

• For the three months ended June 30, 2025, the company reported a net income of $750,303, compared to a net income of $816,754 for the same period in 2024.
• For the six months ended June 30, 2025, the company reported a net loss of - $1,289,691, compared to a net income of $1,603,116 for the same period in 2024.
• Operating costs for the three months ended June 30, 2025, were $76,828, and for the six months ended June 30, 2025, were $211,563.

Cash Flow

• Net cash used in operating activities for the six months ended June 30, 2025, was - $86,218.
• Cash and cash equivalents as of June 30, 2025, were $17,556, down from $103,774 as of December 31, 2024.

Unique Metrics

• The company recorded a loss on issuance of FPA liability of - $1,929,656 and a gain from the change in fair value of FPA liability of $1,123,154 for the six months ended June 30, 2025.

Future Outlook and Strategy

• Core Business Focus: The company is focused on completing its initial business combination, with a proposed merger involving Shenzhen Qianzhi BioTechnology Co. Ltd. The company has extended the deadline for completing this business combination to December 14, 2025.
• Non-Core Business: The company has entered into a Prepaid Forward Purchase Agreement to manage share redemptions and maintain liquidity during the business combination process.
• Priority: The company is prioritizing the completion of its business combination within the extended timeframe to avoid liquidation and dissolution.